BiotechTube
TendoNova

TendoNova

Atlanta, United States· Est.
tendonova.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

TendoNova is a private medical device company commercializing a novel, mechanically oscillating percutaneous tenotomy device for treating chronic tendinopathies like tennis elbow, plantar fasciitis, and rotator cuff issues. The 10-minute in-office procedure is positioned as an alternative to physical therapy, shockwave, or surgery, with clinical data showing 87% of refractory patients reporting positive results. Led by CEO Mark A. Samuels and supported by a board and medical advisors including prominent orthopedic specialists, the company is targeting the large and underserved market of chronic tendon pain.

OrthopedicsSports MedicineMusculoskeletal Disorders

Technology Platform

Percutaneous tenotomy device featuring a novel mechanically oscillating stainless steel cutter for minimally invasive tendon debridement and fragmentation.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The large, underserved market of patients with chronic tendon pain who have failed conservative treatments represents a significant opportunity.
The shift towards in-office, value-based procedures in orthopedics and sports medicine aligns perfectly with TendoNova's 10-minute treatment model, creating potential for rapid adoption and favorable reimbursement pathways.

Risk Factors

Key risks include the challenge of achieving widespread insurance reimbursement and convincing physicians to adopt a new procedural technique.
The company also faces competition from other minimally invasive treatments and must continue to generate robust long-term clinical data to support its efficacy claims and sustain market position.

Competitive Landscape

TendoNova competes in the minimally invasive tendon treatment space against other percutaneous tenotomy devices, extracorporeal shockwave therapy (ESWT), advanced biologic injections (PRP, stem cells), and open surgical procedures. Its differentiation is based on its mechanized, in-office procedure promising precise debridement and a rapid recovery timeline.

More companies in Drug Delivery & Formulation →More companies in United States →